Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2016

View Archived Issues

Apeptico and Mediolanum sign a cooperation and license agreement for solnatide

Amgen and Allergan submit MAA for bevacizumab biosimilar

Ferring Pharmaceuticals and MetaboGen enter research collaboration

Noveome Biotherapeutics begins phase II study of ST-266

BFORE study of bosutinib in CML meets primary endpoint

Purdue Pharma, AnaBios to study compounds for chronic pain

Calimmune and Cincinnati Children's Hospital Medical Center to work together on gene therapies

NeuroDerm gives update on ND-0612 regulatory path

Matinas BioPharma initiates dosing in phase I study of MAT-2501

Adaptimmune starts study of NY-ESO SPEAR-engineered T cells in myxoid/round cell liposarcoma

Promising phase I data presented for SEP-363856 in schizophrenia

Phase II data for verinurad plus febuxostat in patients with gout and asymptomatic hyperuricemia

Omeros provides continued access to OMS-721 for patient with HSCT-TMA

Novo Nordisk submits applications in E.U., U.S. for semaglutide

Sanofi Genzyme begins phase III study of isatuximab

Anti-APRIL monoclonal antibody developed at Visterra for IgA nephropathy

Novogen initiates phase I study of Cantrixil in ovarian cancer

TherapeuticsMD discloses topline results from Replenish trial of TX-001HR

VCN Biosciences' adenovirus expressing hyaluronidase: first clinical data

Further phase I data reported for DS-6051b in patients with solid tumors

Sage expedites development of SAGE-547 for postpartum depression

FDA grants fast track designation to Neovacs' IFN-alpha kinoid in lupus

Harvard College divulges novel CDK8 and/or CDK19 inhibitors

European Commission approves Lucentis for sixth indication

Takeda describes new Toll-like receptor 4 antagonists

The University of Athens identifies novel E-NPP 2 inhibitors

Beijing Institute of Pharmacology and Toxicology patents CB1 receptor antagonists

Shanghai Institute Materia Medica presents new c-Met inhibitors

FDA approves Avastin for platinum-sensitive ovarian cancer

WHO recommends seladelpar as INN for CymaBay's MBX-8025

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...